The immunoassay market is expected to reach 27.15 billion by 2023 from USD 20.19 billion in 2018, at a CAGR of 6.1% during the forecast period.
Will the development of condition-specific biomarkers and tests create opportunities for growth for players in the immunoassay market?
Biomarkers have gained significant clinical value and interest in the medical industry, as they are very useful in the screening, diagnosis, and treatment of diseases. In the diagnosis process, markers can determine staging, grading, and selection of the initial therapy. During treatments, they can be used to monitor therapy, select additional therapies, or monitor recurrent diseases. Technological advancements in genomics, proteomics, and molecular pathology have helped introduce new biomarkers with potential clinical value. The integration of biomarkers and the availability of biomolecular tools are expected to help in the development of a new range of condition-specific tests, thus creating new growth opportunities in the immunoassays market.
Continuous advancements in genomics and proteomics are expected to offer more sophisticated and specialized diagnostic tests. The discovery of new biomarkers for the diagnosis of various diseases, especially cancer, has brought about revolutionary changes in the global medical sector. Also, continuous developments in sequencing technologies and a better understanding of genomics have increased the efficiency of biomarkers in disease detection. This, in turn, is increasing the demand for precision medicine and is expected to offer significant growth opportunities for market players.
Download PDF Brochure – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436
Are complexities in conducting diagnostic tests challenging the growth of the immunoassay market?
Clinical laboratories across major markets are still evolving. As a result, technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as chemiluminescent immunoassay and multiplex flow immunoassay (MFI). Laboratory spaces also need to be reconfigured to meet the requirements of conducting specific immunoassay tests used for pathogen detection as a means of avoiding cross-contamination and ensuring efficient time management. This results in considerable cost escalation to maintain and operate advanced immunoassay instruments, particularly those capable of handling a single sample type.
Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the reluctance to move from manual operations towards automation is another major challenge for market growth.
Request for Sample Pages – https://www.marketsandmarkets.com/requestsampleNew.asp?id=436
Browse Related Reports:
Point-of-Care Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User – Global Forecast to 2022
RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) – Global Forecast to 2022
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Company Name: MarketsandMarkets
Contact Person: Mr. Shelly Singh
Email: Send Email
Address:630 Dundee Road Suite 430
Country: United States